JP2006511516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511516A5 JP2006511516A5 JP2004557217A JP2004557217A JP2006511516A5 JP 2006511516 A5 JP2006511516 A5 JP 2006511516A5 JP 2004557217 A JP2004557217 A JP 2004557217A JP 2004557217 A JP2004557217 A JP 2004557217A JP 2006511516 A5 JP2006511516 A5 JP 2006511516A5
- Authority
- JP
- Japan
- Prior art keywords
- complementarity determining
- region
- amino acid
- humanized
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 26
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims 18
- 102000047882 human INSR Human genes 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 11
- 238000011577 humanized mouse model Methods 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 102000004190 Enzymes Human genes 0.000 claims 4
- 108090000790 Enzymes Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 229960002685 biotin Drugs 0.000 claims 3
- 239000011616 biotin Substances 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 238000007500 overflow downdraw method Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 36
- 125000003275 alpha amino acid group Chemical group 0.000 description 34
- 230000002411 adverse Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/307,276 | 2002-11-27 | ||
| US10/307,276 US7388079B2 (en) | 2002-11-27 | 2002-11-27 | Delivery of pharmaceutical agents via the human insulin receptor |
| PCT/US2003/036870 WO2004050016A2 (en) | 2002-11-27 | 2003-11-18 | Delivery of pharmaceutical agents via the human insulin receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011023913A Division JP5981688B2 (ja) | 2002-11-27 | 2011-02-07 | ヒトインスリン受容体を介する医薬品の送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006511516A JP2006511516A (ja) | 2006-04-06 |
| JP2006511516A5 true JP2006511516A5 (enExample) | 2010-09-02 |
| JP4773097B2 JP4773097B2 (ja) | 2011-09-14 |
Family
ID=32325847
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004557217A Expired - Fee Related JP4773097B2 (ja) | 2002-11-27 | 2003-11-18 | ヒトインスリン受容体を介する医薬品の送達 |
| JP2011023913A Expired - Fee Related JP5981688B2 (ja) | 2002-11-27 | 2011-02-07 | ヒトインスリン受容体を介する医薬品の送達 |
| JP2016014310A Pending JP2016155803A (ja) | 2002-11-27 | 2016-01-28 | ヒトインスリン受容体を介する医薬品の送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011023913A Expired - Fee Related JP5981688B2 (ja) | 2002-11-27 | 2011-02-07 | ヒトインスリン受容体を介する医薬品の送達 |
| JP2016014310A Pending JP2016155803A (ja) | 2002-11-27 | 2016-01-28 | ヒトインスリン受容体を介する医薬品の送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7388079B2 (enExample) |
| EP (1) | EP1569691B1 (enExample) |
| JP (3) | JP4773097B2 (enExample) |
| AU (1) | AU2003295614A1 (enExample) |
| WO (1) | WO2004050016A2 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| PT1583562E (pt) * | 2003-01-06 | 2011-09-19 | Angiochem Inc | Angiopep-1, compostos relacionados, e suas utilizações |
| PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
| EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
| AU2003286870A1 (en) * | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| EP2474317A1 (en) | 2004-06-24 | 2012-07-11 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
| JP2008513497A (ja) * | 2004-09-17 | 2008-05-01 | コメンティス，インコーポレーテッド | メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法 |
| US20080207527A1 (en) * | 2004-09-17 | 2008-08-28 | Comentis, Inc. | Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof |
| CA2604291A1 (en) * | 2005-04-08 | 2006-10-19 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
| ES2434470T3 (es) | 2005-07-08 | 2013-12-16 | Biogen Idec Ma Inc. | Anticuerpos SP35 y usos de éstos |
| RU2422143C2 (ru) | 2005-07-15 | 2011-06-27 | Анджиокем Инк. | Усиление действия противораковых агентов |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| TW200736277A (en) * | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| WO2007091250A2 (en) * | 2006-02-06 | 2007-08-16 | The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center | Enzyme replacement therapy for treating lysosomal storage diseases |
| US8497246B2 (en) | 2006-08-18 | 2013-07-30 | Armagen Technologies, Inc. | Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions |
| US20080200441A1 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| KR20100051668A (ko) * | 2007-07-26 | 2010-05-17 | 코멘티스, 인코포레이티드 | 베타-세크레타제 활성을 억제하는 이소프탈아미드 유도체 |
| EP2997976A1 (en) * | 2007-07-27 | 2016-03-23 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| MX2010002938A (es) * | 2007-09-24 | 2010-04-01 | Comentis Inc | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. |
| ES2610327T3 (es) | 2008-03-13 | 2017-04-27 | Biotest Ag | Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias |
| KR20100135257A (ko) | 2008-03-13 | 2010-12-24 | 바이오테스트 아게 | 질병 치료제 |
| ES2569217T3 (es) | 2008-03-13 | 2016-05-09 | Biotest Ag | Agente para tratar enfermedades |
| PT2279008T (pt) | 2008-04-18 | 2019-05-20 | Angiochem Inc | Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização |
| CA2727790A1 (en) | 2008-06-13 | 2009-12-17 | Synvista Therapeutics, Inc. | Reagents and methods for detecting a polymorphic protein |
| NZ590605A (en) | 2008-07-09 | 2012-11-30 | Biogen Idec Inc | Compositions comprising antibodies to lingo or fragments thereof |
| US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
| CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
| CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
| BRPI0922689A2 (pt) | 2008-12-05 | 2018-11-06 | Angiochem Inc. | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos |
| CN102300987A (zh) | 2008-12-17 | 2011-12-28 | 安吉奥开米公司 | 膜型-1基质金属蛋白抑制剂及其用途 |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| JP5932642B2 (ja) | 2009-07-02 | 2016-06-08 | アンジオケム インコーポレーテッド | 多量体ペプチドコンジュゲートおよびその使用 |
| PL2470199T3 (pl) | 2009-08-28 | 2019-11-29 | Icahn School Med Mount Sinai | Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy |
| US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| JP5885664B2 (ja) | 2009-09-25 | 2016-03-15 | ゾーマ テクノロジー リミテッド | スクリーニング法 |
| JP2013507131A (ja) | 2009-10-09 | 2013-03-04 | アーメイゲン・テクノロジーズ・インコーポレイテッド | Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物 |
| CA2780741C (en) | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| GB0920944D0 (en) * | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
| MX337134B (es) | 2010-05-27 | 2016-02-12 | Janssen Biotech Inc | Peptidos de union al receptor del factor 1 de crecimiento similar a la insulina. |
| US8486399B2 (en) | 2011-12-02 | 2013-07-16 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase A activity in the CNS |
| WO2013110058A2 (en) | 2012-01-20 | 2013-07-25 | Bacha Jeffrey | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma |
| KR102142161B1 (ko) | 2012-05-14 | 2020-08-06 | 바이오젠 엠에이 인코포레이티드 | 운동 뉴런 관련 병태 치료용 lingo-2 길항제 |
| WO2015012944A1 (en) | 2013-07-22 | 2015-01-29 | Armagen Technologies, Inc | Methods and compositions for increasing enzyme activity in the cns |
| MX2016007208A (es) | 2013-12-20 | 2016-07-21 | Hoffmann La Roche | Anticuerpos anti-tau(ps422) humanizados y metodos de uso. |
| US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
| UA120048C2 (uk) * | 2014-03-06 | 2019-09-25 | Нешнл Рісеч Каунсіл Оф Канада | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) |
| DK3114141T3 (da) * | 2014-03-06 | 2020-08-10 | Nat Res Council Canada | Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf |
| US10100117B2 (en) * | 2014-03-06 | 2018-10-16 | National Research Council Of Canada | Insulin-like growth factor 1 receptor-specific antibodies and uses thereof |
| JP2017511376A (ja) | 2014-03-21 | 2017-04-20 | アッヴィ・インコーポレイテッド | 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
| US11130815B2 (en) | 2015-06-24 | 2021-09-28 | Jcr Pharmaceuticals Co., Ltd. | Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody |
| CN113929779B (zh) | 2015-06-24 | 2025-02-25 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
| KR20250073514A (ko) | 2015-06-24 | 2025-05-27 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체 |
| US11207461B2 (en) | 2015-07-30 | 2021-12-28 | Anoop U. R | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier |
| AU2016304588A1 (en) | 2015-08-06 | 2018-02-15 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| CN107465528B (zh) * | 2016-06-03 | 2022-04-15 | 中兴通讯股份有限公司 | 光分配网络odn资源信息采集方法及装置 |
| US20200002432A1 (en) | 2016-06-08 | 2020-01-02 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| JP2019526529A (ja) | 2016-06-08 | 2019-09-19 | アッヴィ・インコーポレイテッド | 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート |
| MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
| UY37278A (es) | 2016-06-08 | 2018-01-31 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos |
| US12145993B2 (en) * | 2016-06-08 | 2024-11-19 | Shanghai Jiao Tong University School Of Medicine | Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity |
| CN110234348B (zh) | 2016-12-16 | 2024-06-25 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| TWI761413B (zh) | 2016-12-26 | 2022-04-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| WO2018124107A1 (ja) | 2016-12-26 | 2018-07-05 | Ｊｃｒファーマ株式会社 | Ｂｄｎｆを含む融合蛋白質 |
| US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| WO2019023056A1 (en) * | 2017-07-24 | 2019-01-31 | Janssen Biotech, Inc. | INSULIN RECEPTOR ANTIBODIES AND USES THEREOF |
| SG11202002730XA (en) | 2017-10-02 | 2020-04-29 | Denali Therapeutics Inc | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2020132452A1 (en) | 2018-12-20 | 2020-06-25 | Shire Human Genetic Therapies, Inc. | Purification of iduronate-2-sulfatase immunoglobulin fusion protein |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| JP2023159049A (ja) | 2022-04-19 | 2023-10-31 | Ｊｃｒファーマ株式会社 | マンノース－６－リン酸の数を減少させた糖蛋白質 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025171378A1 (en) | 2024-02-09 | 2025-08-14 | Rezolute, Inc. | Insulin receptor modulation for tumor associated hyperinsulinism |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US6329508B1 (en) * | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| TW279133B (enExample) * | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US6060069A (en) * | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US6287792B1 (en) * | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| ATE275197T1 (de) * | 1991-09-20 | 2004-09-15 | Amgen Inc | Glial neurotrophe faktor |
| AU677216B2 (en) * | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US5527228A (en) * | 1993-05-24 | 1996-06-18 | Atomic Energy Corporation Of South Africa Limited | Transmission |
| US5997501A (en) * | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| AU6163196A (en) * | 1995-06-07 | 1996-12-30 | Smithkline Beecham Corporation | Method for obtaining receptor agonist antibodies |
| DE69637875D1 (de) * | 1995-09-14 | 2009-04-30 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
| AU719613B2 (en) * | 1995-09-19 | 2000-05-11 | Astellas Pharma Inc. | Aerosol compositions |
| US5837231A (en) * | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
| ATE267257T1 (de) | 1996-11-27 | 2004-06-15 | Genentech Inc | Humanisierte anti-koerper gegen cd11a |
| IL120485A0 (en) * | 1997-03-19 | 1997-07-13 | Yeda Res & Dev | Modulators of the function of receptors of the TNF/NGF receptor family and other proteins |
| AU8269898A (en) | 1997-06-27 | 1999-01-19 | Regents Of The University Of California, The | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
| US6482923B1 (en) | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| US6165783A (en) * | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| US6016800A (en) * | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
| US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| CN1206004C (zh) * | 1997-12-11 | 2005-06-15 | 阿尔扎有限公司 | 增强透皮物剂流量的装置 |
| US6348210B1 (en) * | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| US6284262B1 (en) * | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US7410941B1 (en) * | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US6696274B2 (en) * | 2000-05-03 | 2004-02-24 | Supratek Pharma, Inc. | Ligand for enhancing oral and CNS delivery of biological agents |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| US20030165853A1 (en) * | 2000-12-04 | 2003-09-04 | The Regents Of The University Of California Office Of Technology Transfer | Antisense imaging of gene expression of the brain in vivo |
| US6908902B2 (en) * | 2001-02-02 | 2005-06-21 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| PL362411A1 (en) * | 2001-02-06 | 2004-11-02 | Merck Patent Gmbh | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| JP2005538706A (ja) * | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| US20030129186A1 (en) * | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| EP2316921B1 (en) * | 2002-05-24 | 2014-05-14 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| US7388079B2 (en) | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US7294704B2 (en) * | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| EP1548031A1 (en) * | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| DE102006004008A1 (de) * | 2006-01-27 | 2007-08-02 | Hannelore Prof. Dr. Dr. Ehrenreich | Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose |
| JP2010510794A (ja) * | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| WO2008151841A2 (en) * | 2007-06-15 | 2008-12-18 | University Of Zurich | Treatment for alzheimer' s disease |
-
2002
- 2002-11-27 US US10/307,276 patent/US7388079B2/en not_active Expired - Lifetime
-
2003
- 2003-11-18 JP JP2004557217A patent/JP4773097B2/ja not_active Expired - Fee Related
- 2003-11-18 WO PCT/US2003/036870 patent/WO2004050016A2/en not_active Ceased
- 2003-11-18 EP EP03786812.2A patent/EP1569691B1/en not_active Expired - Lifetime
- 2003-11-18 AU AU2003295614A patent/AU2003295614A1/en not_active Abandoned
-
2007
- 2007-08-14 US US11/893,281 patent/US20080051564A1/en not_active Abandoned
-
2008
- 2008-05-01 US US12/150,983 patent/US8858950B2/en not_active Expired - Lifetime
-
2011
- 2011-02-07 JP JP2011023913A patent/JP5981688B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-28 JP JP2016014310A patent/JP2016155803A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511516A5 (enExample) | ||
| US10882909B2 (en) | Antigen binding constructs to CD3 | |
| JP6964631B2 (ja) | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 | |
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| AU2018214223B2 (en) | Low pH pharmaceutical composition comprising T cell engaging antibody constructs | |
| CN110869393A (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| JP2011509245A5 (enExample) | ||
| CN104105708A (zh) | PDGF受体β结合多肽 | |
| JP2011501656A5 (enExample) | ||
| Li et al. | Natural single-domain antibody-nanobody: a novel concept in the antibody field | |
| KR20230016186A (ko) | 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법 | |
| HRP20171580T1 (hr) | Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba | |
| JP2019537617A5 (enExample) | ||
| JP2021509668A (ja) | 免疫抑制なしにｉｌ−６媒介性炎症を処置する方法 | |
| JP2008521426A5 (enExample) | ||
| JP2006506450A (ja) | 粥状動脈硬化の治療用のペプチドベースの受動免疫療法 | |
| AU2023375340A1 (en) | Methods for the treatment of cardiovascular disease | |
| JP2018531625A5 (enExample) | ||
| CN1946740B (zh) | 抗人腱生蛋白单克隆抗体 | |
| JP2003513985A (ja) | 天然に存在しないエナンチオマー（Ｌ−ビオチン）を結合する抗体および該抗体のターゲッティング薬剤（ａｇｅｎｔ）としての使用 | |
| WO2022060878A1 (en) | Methods for treating prostate cancer | |
| WO2004100882A3 (en) | Inhibition of drug binding to serum albumin | |
| JPWO2019228514A5 (enExample) | ||
| CN119768431A (zh) | Igf1r抗体 |